Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent Lucid expects to report full results for the three and twelve months ended December 31, 2024, in mid-March 2025.

The company raised 2025 total revenue guidance to $310 million–$320 million. Stokes explained that “our normalized revenue growth range in 2025 would be approximately 21% to 26%” when excluding ...

The company’s strategic focus on oncology is evident in its test volume metrics: The Women’s Health segment reported $85.2 million in Q3 revenue, with hereditary cancer testing in the unaffected ...

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements ...